Lantern Pharma Completes Japan Enrollment in Phase 2 Trial for Never-Smoker Lung Cancer Treatment

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to transform oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC clinical trial. The trial evaluates investigational drug candidate LP-300 in never-smoker non-small cell lung cancer patients, a population with significant unmet medical needs.

According to company leadership, this milestone demonstrates excellent execution of Lantern Pharma's international expansion strategy and validates the decision to focus on regions where never-smoker NSCLC has the highest prevalence. The achievement builds momentum as the company continues enrollment in Taiwan and the United States, bringing it closer to generating clinical data that could establish LP-300 as a treatment option for this underserved patient population.

Lantern Pharma's proprietary AI and machine learning platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to solve real-world problems in oncology drug development. The company has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. Additional information about the company is available at https://ibn.fm/LTRN.

The Phase 2 trial represents a significant advancement in addressing lung cancer in never-smokers, a demographic that has historically received less research attention despite the substantial prevalence of the disease in certain regions. The successful enrollment in Japan, completed ahead of schedule, indicates strong execution capabilities and positions the company to potentially bring new treatment options to market more efficiently than traditional drug development approaches.